- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Enrollment change, Trial completion date: Once Weekly GLP-1 in Persons With Spinal Cord Injury (clinicaltrials.gov) - Mar 14, 2023 P4, N=5, Completed, Unknown status --> Completed | N=30 --> 5 | Trial completion date: Dec 2021 --> Mar 2023
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Observational data, Journal, Real-world evidence, Real-world: Once-Weekly Semaglutide Use in Type (Pubmed Central) - Mar 9, 2023 P=N/A Individuals with T2D treated with OW semaglutide experienced significant and clinically relevant improvements in glycaemic control and BW from baseline. These results from a diverse real-world population in the Netherlands support the use of OW semaglutide in treating adults with T2D in routine clinical practice.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial Tokenization Accelerating Innovation in SEPRA () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_840; P4 Approximately half of the participants enrolled in SEPRA had available claims data and their baseline demographics were similar to the overall trial population. The use of this innovative approach within SEPRA provides an example for future research studies wherein multiple data sources are linked to evaluate patient outcomes through tokenization.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Utilization of Glucagon-like Peptide-1 Receptor Agonists in Canada () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_778; Formulary management strategies (prior authorization or prescriber audits) can promote the appropriate use of GLP-1 RAs. Future research in this field should assess if similar patterns are seen with private insurance, if non-T2DM GLP-1 RA use can be detected for individuals circumventing current funding criteria, and the effects of direct-to-consumer advertising on appropriate drug use.
|